← SynDRA
APX-3330
SynDRA canonical compound SYN0020300 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
| Primary target(s) | APEX1 | NFKB1 | NFKB2 |
| Mechanism of action | NFkB pathway inhibitor |
All known targets
Mechanisms of action (all sources)
- APEX1 INHIBITOR
- DNA-(apurinic or apyrimidinic site) lyase inhibitor
- NFkB pathway inhibitor
Cross-references
Synonyms
- APX 3330
- APX3330
- E-3330
- AR-03
- E 3330
- APE1 inhibitors (cancer/retinopathy), ApeX Therapeutics
- APX-3330 analogs (cancer/retinopathy),ApeX Therapeutics
- E-3330 analogs (cancer/retinopathy), ApeX Therapeutics
- E3330
- CHEMBL578390
- UNII-11267UI968
- 11267UI968
- (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid
- (E)-2-((4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylene)undecanoic acid
- (2E)-3-(5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl))-2-nonyl-2-propenoic acid
- SCHEMBL3758716
- SCHEMBL3758719
- HMS3886N15
- EX-A2212
- BDBM50303955
- s7445
- ZINC14252145
- CCG-268389
- HY-19357
- B5875
- CS-0015424
- E3330, >=98% (HPLC)
- A14440
- (E)-3-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dienyl)-2-nonylpropenoic acid
- (E)-3-(5,6-Dimethoxy-3-methyl-14-dioxocyclohexa-25-dienyl)-2-nonylpropenoic Acid
- Undecanoic acid, 2-((4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene)-, (E)-
- Erenapurstat
- APE1/Ref-1 Redox Inhibitor APX3330
- RefChem:558393
- APE1/Ref-1 Inhibitor APX3330
- AALSSIXXBDPENJ-FYWRMAATSA-N
- erenapurstat [INN]
- orb1300433
- GLXC-04561
- HMS6019N05
Look up APX-3330 in the interactive SynDRA portal →